David S. Siegel, MD, PhD

Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.

Nora Biran, MD, and David Siegel, MD, offer closing remarks on the MM treatment landscape.

Myeloma experts share their thoughts on the future of multiple myeloma treatment.

Experts on multiple myeloma compare their treatment sequencing strategies.

Noa Biran, MD, offers insights on ongoing research with bispecific antibodies in multiple myeloma.

A comprehensive discussion on bispecific antibodies and T-cell engagers in the treatment of multiple myeloma.

Myeloma experts give an overview of allogeneic CAR T-cell therapy and other technology advances in MM.

Noa Biran, MD, and David Siegel, MD, discuss how CAR T-cell availability has impacted the field of multiple myeloma.

Experts on multiple myeloma discuss available BCMA-targeted CAR T-cell therapies and the KarMMa and CARTITUDE-1 clinical trials.

Noa Biran, MD, and David Siegel, MD, review the shifting treatment paradigms in multiple myeloma (MM).

In this interview we discuss the standard of care and current treatment options for patients with multiple myeloma.

In this interview we discuss the latest therapy developments in the treatment of multiple myeloma.

This series of articles provides clinicians with a resource for the use of carfilzomib in the management of patients with multiple myeloma.